Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18
description
Transcript of Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18
![Page 1: Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18](https://reader036.fdocuments.in/reader036/viewer/2022062518/56813f9e550346895daa8ef5/html5/thumbnails/1.jpg)
Characteristics of Large Prospective Randomized Controlled Statin Trials Included in the Present Analysis
Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18
![Page 2: Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18](https://reader036.fdocuments.in/reader036/viewer/2022062518/56813f9e550346895daa8ef5/html5/thumbnails/2.jpg)
Relationship Between Rates of ElevatedLiver Enzymes and % LDL-C Reduction
Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18
![Page 3: Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18](https://reader036.fdocuments.in/reader036/viewer/2022062518/56813f9e550346895daa8ef5/html5/thumbnails/3.jpg)
Relationship Between Rates ofRhabdomyolysis and % LDL-C Reduction
Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18
![Page 4: Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18](https://reader036.fdocuments.in/reader036/viewer/2022062518/56813f9e550346895daa8ef5/html5/thumbnails/4.jpg)
Rate of Elevated LiverEnzymes by Statin Dose Category
Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18
![Page 5: Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18](https://reader036.fdocuments.in/reader036/viewer/2022062518/56813f9e550346895daa8ef5/html5/thumbnails/5.jpg)
Rate of Elevated LiverEnzymes by Lovastatin Dose Category
Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18
![Page 6: Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18](https://reader036.fdocuments.in/reader036/viewer/2022062518/56813f9e550346895daa8ef5/html5/thumbnails/6.jpg)
Rate of Elevated LiverEnzymes by Simvastatin Dose Category
Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18
![Page 7: Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18](https://reader036.fdocuments.in/reader036/viewer/2022062518/56813f9e550346895daa8ef5/html5/thumbnails/7.jpg)
Rate of Elevated LiverEnzymes by Atorvastatin Dose Category
Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18
![Page 8: Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18](https://reader036.fdocuments.in/reader036/viewer/2022062518/56813f9e550346895daa8ef5/html5/thumbnails/8.jpg)
Characteristics of Large Prospective Randomized Controlled Statin Trials in Which Incident Cancer Rates Were
Reported, and Used for the Present Analysis
Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18
![Page 9: Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18](https://reader036.fdocuments.in/reader036/viewer/2022062518/56813f9e550346895daa8ef5/html5/thumbnails/9.jpg)
Relationship Between Rates of Newly Diagnosed Cancer per 100,000 Person-Years and % LDL-C
Reduction
Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18
![Page 10: Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18](https://reader036.fdocuments.in/reader036/viewer/2022062518/56813f9e550346895daa8ef5/html5/thumbnails/10.jpg)
Relationship Between Rates of Newly Diagnosed Cancer per 100,000 Person-Years and Absolute LDL-C
Reduct
Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18
![Page 11: Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18](https://reader036.fdocuments.in/reader036/viewer/2022062518/56813f9e550346895daa8ef5/html5/thumbnails/11.jpg)
Relationship Between Rates of Newly Diagnosed Cancer per 100,000 Person-Years and Achieved LDL-C
Level
Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18
![Page 12: Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18](https://reader036.fdocuments.in/reader036/viewer/2022062518/56813f9e550346895daa8ef5/html5/thumbnails/12.jpg)
Rate of Newly DiagnosedCancer by Statin Dose Category
Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18
![Page 13: Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18](https://reader036.fdocuments.in/reader036/viewer/2022062518/56813f9e550346895daa8ef5/html5/thumbnails/13.jpg)
References
Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18